Boundless Bio Inc. Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Boundless Bio Inc. (BOLD) reported its Q3 2025 financial results, showing a net loss of $13.9 million, an improvement from $16.5 million in Q3 2024. The company, focused on therapies for oncogene-amplified cancers, is advancing its pipeline, including ongoing enrollment in the POTENTIATE trial and plans for a first-in-human trial for BBI-940 in 2026. With $117.6 million in cash, Boundless Bio aims to deliver proof-of-concept data while maintaining a robust cash position through mid-2028, remaining optimistic about its impact on patients and shareholders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments